Global Liquid Biopsy Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The global liquid biopsy market size is expected to reach USD 19.23 Billion in 2034 from USD 6.78 Billion in 2025, growing at a CAGR of 12.28 during 2026-2034.This market is experiencing rapid growth as healthcare providers increasingly adopt minimally invasive diagnostic technologies for cancer detection and disease monitoring. Liquid biopsy enables the analysis of circulating tumor DNA, circulating tumor cells, and other biomarkers through blood samples, offering a faster and less invasive alternative to traditional tissue biopsies. Rising cancer prevalence, growing demand for precision medicine, and continuous advancements in molecular diagnostics are driving widespread adoption across healthcare systems. Expanding research in oncology and personalized treatment strategies is further supporting market development.

Technological innovations in next-generation sequencing, polymerase chain reaction, and biomarker analysis are improving the accuracy and reliability of liquid biopsy testing. Pharmaceutical companies and research institutions are utilizing these technologies to support drug development, treatment monitoring, and early disease detection. Increasing investments in clinical research, favorable regulatory support, and expanding applications beyond oncology are creating significant growth opportunities. Integration with artificial intelligence and bioinformatics platforms is further enhancing diagnostic efficiency.

The future outlook remains highly promising as precision healthcare and early disease detection continue gaining importance worldwide. Advances in genomic technologies, automation, and multi-cancer screening solutions will expand clinical applications and improve patient outcomes. Increasing healthcare investments, rising awareness of non-invasive diagnostics, and continuous innovation in biomarker research will strengthen long-term market growth. Liquid biopsy is expected to become an integral component of personalized healthcare and disease management.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

Consumables (Kits and Reagents, Assays and Panels)
Instruments
Services

By Biomarkers

Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
Extracellular Vesicles
Other Biomarkers

By Disease Indication

Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers)
Non-Cancer (Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing)

By Clinical Application

Treatment Monitoring
Prognosis and Recurrence Monitoring
Treatment Selection
Diagnosis and Screening

By Technology

Multi-Gene Parallel Analysis (NGS)
Single-Gene Analysis (PCR, Microarrays)

By End User

Hospitals
Research Laboratories
Clinical Laboratories
Other End Users

COMPANIES PROFILED

ANGLE plc, Biocept, Bio-Rad Laboratories, Epigenomics AG, F. Hoffmann-La Roche, Freenome Holdings, GRAIL, Guardant Health, Illumina, Lucence Health, MDxHealth, Menarini group, Myriad Genetics, Natera, QIAGEN, Sysmex Corporation, Thermo Fisher Scientific

Product Code: VMR112119258

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL LIQUID BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product
4.2. Consumables (Kits and Reagents, Assays and Panels) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LIQUID BIOPSY MARKET: BY BIOMARKERS 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Biomarkers
5.2. Circulating Tumor Cells (CTCs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Circulating Tumor DNA (ctDNA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Cell-Free DNA (cfDNA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Extracellular Vesicles Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.6. Other Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LIQUID BIOPSY MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Disease Indication
6.2. Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers) Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Non-Cancer (Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast Clinical Application
7.2. Treatment Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Prognosis and Recurrence Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Treatment Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Diagnosis and Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LIQUID BIOPSY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

8.1. Market Analysis, Insights and Forecast Technology
8.2. Multi-Gene Parallel Analysis (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.3. Single-Gene Analysis (PCR, Microarrays) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LIQUID BIOPSY MARKET: BY END USER 2022-2034 (USD MN)

9.1. Market Analysis, Insights and Forecast End User
9.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.4. Clinical Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL LIQUID BIOPSY MARKET: BY REGION 2022-2034 (USD MN)

10.1. Regional Outlook
10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.2.1 By Product
- 10.2.2 By Biomarkers
- 10.2.3 By Disease Indication
- 10.2.4 By Clinical Application
- 10.2.5 By Technology
- 10.2.6 By End User
- 10.2.7 United States
- 10.2.8 Canada
- 10.2.9 Mexico
10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.3.1 By Product
- 10.3.2 By Biomarkers
- 10.3.3 By Disease Indication
- 10.3.4 By Clinical Application
- 10.3.5 By Technology
- 10.3.6 By End User
- 10.3.7 United Kingdom
- 10.3.8 France
- 10.3.9 Germany
- 10.3.10 Italy
- 10.3.11 Russia
- 10.3.12 Rest Of Europe
10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.4.1 By Product
- 10.4.2 By Biomarkers
- 10.4.3 By Disease Indication
- 10.4.4 By Clinical Application
- 10.4.5 By Technology
- 10.4.6 By End User
- 10.4.7 India
- 10.4.8 Japan
- 10.4.9 South Korea
- 10.4.10 Australia
- 10.4.11 South East Asia
- 10.4.12 Rest Of Asia Pacific
10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.5.1 By Product
- 10.5.2 By Biomarkers
- 10.5.3 By Disease Indication
- 10.5.4 By Clinical Application
- 10.5.5 By Technology
- 10.5.6 By End User
- 10.5.7 Brazil
- 10.5.8 Argentina
- 10.5.9 Peru
- 10.5.10 Chile
- 10.5.11 Rest of Latin America
10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.6.1 By Product
- 10.6.2 By Biomarkers
- 10.6.3 By Disease Indication
- 10.6.4 By Clinical Application
- 10.6.5 By Technology
- 10.6.6 By End User
- 10.6.7 Saudi Arabia
- 10.6.8 UAE
- 10.6.9 Israel
- 10.6.10 South Africa
- 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

11.1. Recent Developments
11.2. Company Categorization
11.3. Supply Chain & Channel Partners (based on availability)
11.4. Market Share & Positioning Analysis (based on availability)
11.5. Vendor Landscape (based on availability)
11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL LIQUID BIOPSY INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Company Profiles
- 12.2.1 ANGLE Plc
- 12.2.2 Biocept
- 12.2.3 Bio-Rad Laboratories
- 12.2.4 Epigenomics AG
- 12.2.5 F. Hoffmann-La Roche
- 12.2.6 Freenome Holdings
- 12.2.7 GRAIL
- 12.2.8 Guardant Health
- 12.2.9 Illumina
- 12.2.10 Lucence Health
- 12.2.11 MDxHealth
- 12.2.12 Menarini Group
- 12.2.13 Myriad Genetics
- 12.2.14 Natera
- 12.2.15 QIAGEN
- 12.2.16 Sysmex Corporation
- 12.2.17 Thermo Fisher Scientific